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lization data. Results: The review allowed retrieving 4,768 studies and 11 fulfilled 
the eligibility criteria. Two articles presented their results in terms of correlation 
coefficient that were all statistically significant. The first one determined a correla-
tion between FEV1 and inhaled corticosteroids (ICS) use with an R-value of -0.42 and 
between sputum eosinophils and ICS use with an R-value of 0.3. The second article 
evaluated the correlation between PEF and hospitalization rates and concluded to 
a correlation with an R-value of -0.51. A total of 9 articles presented raw data that 
could be used to establish a correlation between lung function or eosinophil levels 
and resource utilization. Seven studies presented data that indicate an inverse cor-
relation between FEV1 and hospitalizations with decreased hospitalization rates, 
when FEV1 increases. Three studies indicate decreased emergency departments 
visit rates when FEV1 increases. Two studies also indicate an increased emergency 
department visit rates, when blood eosinophil levels increase. ConClusions: 
The correlation coefficients found in the systematic review indicate that when 
lung function improves or sputum eosinophil decreases, the resource utilization 
decreases. Furthermore, non-correlation studies that look at the same parameters 
support this hypothesis and suggest there may be a correlation between emergency 
department’s visits and blood eosinophil levels.
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objeCtives: The characteristic properties of the modern healthcare system are 
presented by integration of information technology capabilities and harmonization 
of their use in industry. Aim. To create new system of telecommunication interaction 
between doctor and patient – specialized internet portal. Methods: The study was 
carried out to create web portal. The software project - shell management website 
with two interfaces: for professionals and patients was developed. Simultaneously 
with design and creation of an internet portal, 156 children with bronchial asthma 
(BA) were examined and their medical data were reviewed. Results: 19 children 
with severe atopic persistent uncontrolled BA (68% boys; mean age 13.6; basic 
therapy - 875 mcg fluticasone in combination with long-acting ß2-agonist and 
Omalizumab, the average dose - 450 mg / 4 weeks) were included in the project and 
had received the personal individual access (a couple of unique login/password to 
own page). The personal page after entering the own individual login / password 
allows patient to type in synchronous/asynchronous mode indicators of peak flow, 
symptoms, using of basic therapy and rescue medication in a special tables, the 
level of asthma control (ACT- test), and remotely – to ask a question to specialist. 
Patients with severe BA exacerbations, who were in the intensive care unit, also 
patients who don’t perceive long-term significant decline in respiratory function, 
had issued devices to determine oxygen saturation (SpO2, pulsoximeter) to moni-
tor this indicator and to exclude development of life-threatening conditions. The 
specialist interface contains information about each patient to evaluate remotely 
in synchronous/asynchronous mode patient condition, therapy adherence and con-
trol of BA ConClusions: The results of preliminary analysis of using of this web 
portal show increase of adherence to prescribed treatment, improving of quality of 
life, reduction the incidence of exacerbations, that confirms clinical and economic 
feasibility of using internet technologies.
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objeCtives: Previous research to determine the effectiveness of web or computer 
based interventions, designed to reduce smoking have been reported. However, 
a lacuna regarding the use of same during consultations exists. The objective 
of this review was to improve understanding of the role of clinical computing 
systems during consultations on smoking cessation in general dental, medical, 
and community based practices or hospitals. Methods: The Cochrane Library, 
PubMed, ISI Web of Knowledge, EMBASE, and Google Scholar were accessed up to 
January 2010 using a combination of various Medical Subject Headings and other 
keywords to retrieve relevant studies not restricted to any geography. Studies 
were included based on a range of predefined inclusion criteria. Each study was 
quality scored (0-10) using a validated scoring system. The PRISMA checklist was 
used as the critical appraisal tool. Pre-developed forms were employed for extract-
ing the data. Results: Five studies fulfilled the selection criteria. A descriptive 
comparison was drawn between different studies since a meta-analysis was not 
possible as results for the I2 statistic were approximately 50%, indicating moder-
ate heterogeneity. A comparison of interventions was performed after extracting 
data from two studies using ExcelTM spread sheets, and presented as a forest 
plot. Findings indicated positive impact of clinical computing systems in physi-
cian consultations in increasing smoking abstinence in patients by 2% in clinical 
decision support system (CDSS) to up to 12 % (tailored letters). ConClusions: 
Tailored letters proved more effective when compared to brief advice and CDSS. 
Multi-faceted approaches involving elements of behavioral sciences, epide-
miology, health promotion and health informatics will be the key for future 
research.
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hospital admissions. Results: The study cohort included 36,914 patients (GOLD 
A: 33.8%, GOLD B: 21.0%, GOLD C: 18.1%, GOLD D: 27.0%). Average age at diagnosis 
was 66 years; 52.0% were male. Annual exacerbation rates increased with sever-
ity of COPD, ranging from GOLD A 0.83 (95% CI: 0.81–0.85) to GOLD D 2.51 (95% 
CI: 2.47–2.55) exacerbations per person-year (PPY). Annual rates of GP visits also 
increased with disease severity, from GOLD A 4.82 (95% CI: 4.74–4.93) to GOLD D 
7.44 (95% CI: 7.31–7.61) visits PPY. COPD-related hospitalisations increased with 
symptom severity from less (GOLD A: 0.28, GOLD C: 0.39 admissions PPY) to more 
symptoms (GOLD B: 0.52, GOLD D: 0.84 admissions PPY). No differences were 
observed across severity groups in non-COPD hospitalisations. ConClusions: 
Patients in the most severe category (GOLD D) experienced nearly three times the 
number of exacerbations and COPD-related hospital admissions as those in the 
least severe category (GOLD A). Management of COPD in earlier stages to stabilize 
disease progression could be beneficial for reducing exacerbation frequency and 
healthcare resource utilisation.
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objeCtives: To compare the total value of payer’s expenditures on Nutramigen 
LGG 1, Nutramigen LGG 2, Neocate LCP, Neocate Advance in patients with allergy to 
cow’s milk protein estimated in the manufacturers’ Budget Impact Analyses (BIAs) 
submitted with the reimbursement applications to AOTMiT and actual expenditures 
of the National Health Fund (NHF). Methods: Annual public payer’s expenditures 
estimated in manufacturers’ BIAs for Nutramigen LGG 1/2, Neocate LCP/Advance 
and actual expenditures reported by the NHF were compared. RSSs were not taken 
into account. Analysed drugs were chosen on the basis of the same indication. 
Actual expenditures and number of package were taken from the financial reports of 
the NHF for the first and second year of the reimbursement for each drug. Results: 
For drugs Nutramigen LGG1/2 and Neocate LCP/Advance in patients with allergy 
to cow’s milk protein, the sum of total expenditures estimated in BIA submitted 
with the reimbursement applications was 55,158 million PLN in the first year and 
57,637 million PLN in the second year, and they were higher than the actual expen-
ditures reported by the NHF: 5,3 million PLN and 16,14 million PLN, respectively. 
The expenditures estimated in BIAs were overestimated by 939% in the first year 
of the reimbursement and 257% in the second year of reimbursement. The number 
of packages of the Nutramigen LGG 1/2, Neocate LCP/Advance also were analysed. 
The number of reimbursed packages estimated in BIAs in comparison to its actual 
number from the NHF reports was overestimated by 2029% in the first year and 
492% in the second year of reimbursement. ConClusions: In the case of drugs 
chosen for this analysis, total payer’s expenditures estimated in BIAs submitted with 
the reimbursement applications were overestimated in comparison to the real life 
expenditures of the NHF in Poland.
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objeCtives: Patients with COPD in their final months of life place a potentially 
high burden upon healthcare systems. The aim of this systematic review was to 
describe the resources used and costs incurred by patients with COPD at the end-
of-life. Methods: We performed a comprehensive literature search in Medline, 
Web of Science and Econlit and evaluated and synthesized existing evidence on 
resource use and costs at the end-of-life in COPD patients. We screened 886 abstracts 
and reviewed 80 full-text manuscripts. Inclusion criteria were at least one type of 
resource use and/or cost outcome reported in adults diagnosed with COPD during an 
end-of-life period (varying between 3 years and 2 weeks before death). Subsequently, 
we performed quality appraisal consistent with the ISPOR checklist for retrospec-
tive database studies and accomplished comprehensive data extraction. Results: 
Nine studies fulfilled the inclusion criteria. Two, five and two studies described a 
European, North American and Asian healthcare setting, respectively. All studies 
had a retrospective design and were published between 2006 and 2014. We observed 
a very variable use of healthcare resources. An increased number of hospitaliza-
tions, ICU stay, primary care consultations and medication prescriptions and a lack 
of utilization of formal palliative care services were found to be the key drivers 
of resource use and costs of COPD patients during end-of-life. Palliative care also 
had a positive impact on costs in those patients. ConClusions: Despite a small 
number of existing studies, we found that the extensive and variable resource use 
and related costs of COPD patients during end-of-life applies to different aspects 
of the healthcare system. Especially the use of palliative care services is presumed 
to be effective in cost reduction at the end-of-life.
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objeCtives: Asthma is a very common chronic disease that can cause a significant 
economic burden. The objective of this review was to explore the evidence on the 
possible correlation between lung function or eosinophil levels and resource utiliza-
tion in asthmatic patients. Methods: A literature search was made using keywords 
such as “asthma”, “eosinophil”, “respiratory function”, “resources”, and “costs”. The 
search was conducted in the electronic databases MEDLINE, EMBASE and PubMed 
from January 2000 to February 10th, 2015. To be eligible, studies had to focus on asth-
matic patients, include pulmonary or eosinophil measurements, and resource uti-
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In clinical practice and screening programs, variations between one equation and 
another, specifically in early stages of CKD, should be considered.
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objeCtives: Exploratory studies suggest that mineralocorticoid-receptor antago-
nists (MRAs) may improve outcomes in patients with diabetic kidney disease (DKD). 
Finerenone (BAY 94-8862) is a selective, potent and non-steroidal MRA for the treat-
ment of patients with DKD, currently studied in two clinical phase III trials. Early 
modeling investigated the implications of using finerenone in addition to standard 
of care. Methods: A Markov cohort model was used to emulate disease history, 
treatment effects, and outcomes for DKD patients with various disease severi-
ties (by albuminuria, measured by urinary-albumin-creatinine ratio [UACR], and 
chronic kidney disease [CKD] stage, measured by estimated glomerular filtration 
rate [eGFR]). Efficacy of finerenone is accomplished by reducing UACR, evidenced by 
phase 2 trial data. The model has UK settings; inputs are from NHANES 1999-2008, 
adapted to UK population, USRDS 2009, various registries, and trials. Sensitivity 
analyses explored which patient subpopulation would benefit to what extent from 
finerenone treatment. Results: The model predicts that finerenone is an effective 
treatment option for DKD patients, primarily by virtue of reduced risk of end-stage 
renal disease (ESRD) and renal death (absolute risk reductions [ARR] of up to 8.3% 
and 8.2%, respectively, for advanced DKD, i.e. macro-albuminuria and CKD3/4) and 
increased health-related quality of life, and that it would generate cost savings on 
renal replacement therapy (up to £5,353 for advanced DKD). From a clinical out-
comes perspective the optimal time point to begin finerenone treatment appears 
to be after patients have progressed to either macro-albuminuria or CKD stage 3, as 
represented by both phase III trial populations. Reduced CV events and CV mortality, 
however, are greatest (ARR of up to 3.7% and 4.7%, respectively) when finerenone 
treatment is started in CKD stages 3 or earlier. ConClusions: Treatment with the 
MRA finerenone appears to be of significant benefit to patients and the healthcare 
system, particularly if initiated in advanced stages of DKD.
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objeCtives: The aim of the OCEANE non interventional study was to describe in real 
life conditions the management of anaemia with C.E.R.A. in patients with chronic 
kidney disease not on dialysis. We used data from this study to perform exploratory 
analysis to evaluate factors influencing haemoglobin levels. Methods: To iden-
tify these factors, supervised and unsupervised data mining models and statisti-
cal approaches such as Random forest, hypercube analysis, Bayesian networks and 
mixed model for repeated measures were used. For supervised analysis, the targeted 
outcome measure was the haemoglobin level around 6 month of treatment, using 
EMA guidelines (haemoglobin level between [10-12] g/dL). As treatment patterns are 
very different, analyses have been performed by subgroup of patient naïve or not of 
ESA. Patients were followed up every 3 months during 1 year. Results: 616 adult 
patients were included/followed in the OCEANE study between 2009 and 2011, 609 
patients were taken into account for these analyses (haemoglobin available at base-
line) and 44% were ESA-naïve. 44% of patients without transfusion had a haemoglobin 
level within 10–12 g/dL around 6 months of treatment. For ESA-naïve patients, most 
patients with a haemoglobin level lower than 10 g/dL at 3 months remained below the 
target at 6 months. Regarding non ESA-naïve patients, most patients with a haemo-
globin level greater than 12 g/dL at 3 months remained above the target at 6 months. 
Dose adjustments were not performed for 2/3 of patients around 3 months when 
haemoglobin was outside the target range. ConClusions: These techniques on real 
world data seems to be a way to broaden the pathology, compound and practice pat-
terns interactions. Dose adjustment around 3 months of treatment is a key factor for 
achieving the recommended haemoglobin target after 6 months. Our study confirms 
the importance of personalized anaemia management based on the patient’s profile.
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objeCtives: This study aims to determine the patterns of medication use in 
patients with chronic kidney disease (CKD) stage 5D with special focus on drugs 
for the management of chronic kidney disease-mineral and bone disorder (CKD-
MBD). Methods: A retrospective, observational study was conducted at Hospital 
Universiti Sains Malaysia. Medical records of 134 adult patients with CKD stage 5D 
were reviewed from January-April, 2014. Data regarding patient’s demographics, 
co-morbidities and medications were collected. The medications prescribed were 
classified according to the Anatomic Therapeutic Chemical classification recom-
mended by World Health Organization. The drugs were further categorized as clinic 
and home medications. Comparisons were made between age groups (≤ 50 or > 50 
years), gender and diabetic status. Results: Patients were 52.97 ± 14.05 years old, 
and were prescribed 12.88 ± 4.14 medications (10.00 ± 2.88 home medications and 
2.88 ± 2.99 clinic medications). Patient’s gender had no influence on the number of 
prescribed medications. However, patients with diabetes and elderly patients were 
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objeCtives: To determine the prescribing pattern of specialized physicians for 
tuberculosis in Punjab, Pakistan. Methods: A drug utilization study was conducted 
at community pharmacies among tuberculosis patients attending tertiary hospitals. 
A stratified sampling technique was used for selecting community pharmacies. 
Prescriptions written by tuberculosis specialized physicians were collected and 
analyzed according to WHO standard treatment guidelines. Results: The data 
were gathered from 750 prescriptions. Unfair number of drugs were prescribed 
in which the mean number of drugs in a single prescription was 7.0 (+2.1). The 
value of prescribing indicators was more than the WHO standard indicators. Most 
of the prescribed medicines (95%) were written in their brand names. Moreover, 
the frequently prescribed medicines were antibiotics (37.7%); anxiolytics (23.5%); 
and corticosteroids (29%). ConClusions: Physicians’ adherence to the standard 
practicing guidelines was poor although the affordability of medicines was fair but 
still the prescribing pattern needs to be apposite. Implementation of administra-
tive strategies to improve the current prescribing pattern as well as patient-educa-
tional programs concerning the tuberculosis treatment are of utmost importance. 
In addition, further studies are required in other provinces of Pakistan in order to 
understand the complete prescribing behavior of the physician to treat tuberculosis 
throughout the country.
uRinARy/kidney diSORdeRS – clinical Outcomes Studies
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objeCtives: The aim of the study was to investigate 1) if the average Pakistanis and 
average Italian kidney post transplanted patients have same episodes of adverse 
events after intake of cyclosporine,tacrolimus and corticosteroids 2) and to green 
light the safest as well as hazardous drug among these three with appropriate rea-
sons for effectiveness and ineffectiveness. Methods: The subjects were randomly 
selected including 706 pakistani and 568 italian patients both male and female with 
inclusion criteria of teen age and geriatric patients.Blood sample was taken from 
each subject in order to determine the amount of creatinine,glucose,hemoglobin 
and cholesterol.Urine sample was also taken in order to determine level of pro-
tein.Also Delayed Graft Function (DFG) was observed in these subjects. Results: 
Thirty one percent of Italian men and 26% of Italian women suffered from hyper-
creatininemia and hyperproteinuria including hemoglobinemia and hyper-
cholesterolemia whereas 22% of Pakistani men and 21.50% of Pakistani women 
experienced same adverse effects.It was observed that majority of adverse effects 
were found between age group 46-55 and found to be least between age group 
17-25. ConClusions: It was concluded that for immuno-compromised patients 
DGF,mortality rate and risk of transplant failure has been shown minimum for 
corticosteroids,intermediate for tacrolimus and maximum for cyclosporine and 
for immuno-competent patients,tacrolimus was effective drug. As cyclosporine 
which is composed of 11-amino acids,is followed by a competitive receptor bind-
ing with proteins whose level exceeds the upper limit in abnormal kidney function 
and hence those amino acids having same ‘R’ functionality with attaching side 
of cyclosporine will compete leading to unavailability of cyclosporine.Also it was 
observed that patient’s adherence was maximum with corticosteroids as they pro-
duce synergistic effect with adrenal gland’s steroid production.These data suggest 
that immuno-suppressants should be monitored with special care depending upon 
the immune status of patient.
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objeCtives: In order to determine the GFR different equations had been used, 
mainly CG, the MDRD and CKD-EPI; with differences in estimation of renal func-
tion by these equation, therefore we defined to determine the correlation between 
these to estimate GFR in patients with hypertension (HT), diabetes (DM) or some 
stage of chronic kidney disease (CKD). Methods: Data from 3.055.568 patients 
over 18 years with HT, DM and CKD was used. Prediction limits for differences 
between pairs of measurements using the limits according to Bland and Altman 
were calculated and plotted, the valuesLin correlation coefficients between MDRD- 
CG, CG-CKD/EPI and CKD/EPI-MDRD couples, considering that the three methods 
provide results measurement in the same scale. Results: 1.348.214 patients were 
included, 832.129 women (61.7%). The age mean was 64.3 years (standard deviation 
(SD) 13.2), 50% of patients were between 60 and 74 years old. 94% had diagnosis of HT 
and 26% of DM. The intraclass correlation coefficient (ICC) between CG and DMRD 
was 0.704 with 95% of (0.703- 0.705) with a difference mean of 3.5 and Bland and 
Altman agreed limits from -31.65 to 43.83; ICC being CG and CKD-EPI is 0.728 with 
a CI 95% (0.729-0.730) with a difference mean of 1.73 and Bland and Altman agreed 
limits from -37.26 to 40.62 and correlation coefficient being intraclass CKD-EPI and 
MDRD is 0.855 with 95% of (0.855, 0.856) with a difference mean of -1.86 and Bland 
and Altman agreed limits from -25.61 and 21.89. ConClusions: General popula-
tion studies have reported a good correlation comparison between DRMD and CKD 
-EPI, our results in CKD population and precursor disease, also have shown a good 
correlation between them. Similar findings have been observed in other reports. 
